ArticleBritish journal of cancer2026
Impact of tumor location on the efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcurrent chemoradiotherapy (cCRT) is a pivotal component in locally advanced non-small cell lung cancer (NSCLC) treatment; however, exploration of factors that impact its efficacy has been limited.
methodsWe analyzed individual data of 1165 patients with locally advanced NSCLC enrolled in randomized phase II/III trials of cCRT between 1999 and 2016. Least absolute shrinkage and selection operator (LASSO) regression was applied to identify factors associated with 3-year progression-free survival (PFS). Cox regression was applied to adjust for key clinical variables.
resultsThe 3- and 5-year PFS rates were 19.7% and 14.3%, respectively (median PFS: 9.7 months). The 3- and 5-year overall survival rates were 56.7% and 42.9%, respectively (median OS: 25.7 months). LASSO regression identified age, lower lobe tumor location, weight loss (≥5% within 6 months), smoking index, and histology as predictors of PFS. Lower lobe tumors and weight loss independently predicted shorter PFS (lower lobe: hazard ratio 1.29; 95% CI, 1.02-1.64; P = 0.036). Lower lobe tumors also had more pneumonitis (55.8% vs. 43.4%; grade ≥3: 11.0% vs. 4.3%) and in-field recurrence (60.2% vs. 51.4%).
conclusionPrimary tumor location should be carefully considered in clinical practice and during the development of treatment strategies for locally advanced NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.